317 related articles for article (PubMed ID: 28515111)
1. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
2. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
Farias AJ; Du XL
Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
[TBL] [Abstract][Full Text] [Related]
3. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
4. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
Farias AJ; Wu WH; Du XL
BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
[TBL] [Abstract][Full Text] [Related]
5. Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
Tan X; Camacho TF; LeBaron VT; Blackhall LJ; Balkrishnan R
Breast Cancer Res Treat; 2017 Sep; 165(2):455-465. PubMed ID: 28639031
[TBL] [Abstract][Full Text] [Related]
6. Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer.
Farias AJ; Wu WH; Du XL
Med Oncol; 2018 Jun; 35(7):113. PubMed ID: 29926275
[TBL] [Abstract][Full Text] [Related]
7. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
[TBL] [Abstract][Full Text] [Related]
9. Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
Saraf A; Tahir I; Hu B; Dietrich AW; Tonnesen PE; Sharp GC; Tillman G; Roeland EJ; Nipp RD; Comander A; Peppercorn J; Fintelmann FJ; Jimenez RB
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):94-103. PubMed ID: 37506979
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
11. Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
Lee KT; Jacobs L; Walsh EM; Stearns V; Segal JB
Breast Cancer Res Treat; 2020 Dec; 184(3):965-975. PubMed ID: 32914353
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy].
Xia G; Zhu J; Yuan J; Cao B; Tang J; Chen Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(6):614-619. PubMed ID: 28247605
[TBL] [Abstract][Full Text] [Related]
13. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
[TBL] [Abstract][Full Text] [Related]
14. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
[TBL] [Abstract][Full Text] [Related]
16. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
17. Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative.
Livaudais JC; Lacroix A; Chlebowski RT; Li CI; Habel LA; Simon MS; Thompson B; Erwin DO; Hubbell FA; Coronado GD
Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):365-73. PubMed ID: 23275187
[TBL] [Abstract][Full Text] [Related]
18. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
Livaudais JC; Hershman DL; Habel L; Kushi L; Gomez SL; Li CI; Neugut AI; Fehrenbacher L; Thompson B; Coronado GD
Breast Cancer Res Treat; 2012 Jan; 131(2):607-17. PubMed ID: 21922245
[TBL] [Abstract][Full Text] [Related]
19. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
[TBL] [Abstract][Full Text] [Related]
20. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]